SHAN 5

Indications

• Cancer (e.g., leukemia, lymphoma)
• Autoimmune diseases (e.g., lupus, rheumatoid arthritis)
• Cardiovascular diseases (e.g., myocardial infarction)
• Neurological disorders (e.g., Parkinson's disease, multiple sclerosis)
• Orthopedic conditions (e.g., osteoarthritis)
• Genetic disorders (e.g., cystic fibrosis)

Dosage

Children: Dosage varies widely based on the cell type and condition being treated. Refer to specific treatment protocols and guidelines.

Adults: Dosage varies widely based on the cell type and condition being treated. Refer to specific treatment protocols and guidelines.

Mechanism of action

Cell therapies can function through several mechanisms, including differentiation into specific cell types, secretion of bioactive factors that promote tissue repair, and modulation of the immune response. For example, in the case of stem cells, they can migrate to sites of injury and contribute to tissue regeneration and repair.

Pharmacodynamics

The pharmacodynamics of cell therapy depend on the type of cells used and their intended purpose. For immune cell therapies, such as CAR T-cell therapy, the activated T-cells seek out and destroy cancer cells. In regenerative medicine, stem cells can differentiate into various cell types, potentially restoring normal function in damaged tissues. The therapeutic effects may also be mediated through paracrine signaling, where the cells release signaling molecules that enhance healing processes.

Pharmacokinetics

The pharmacokinetics of cell therapies include factors such as cell migration, engraftment, and survival within the host. After administration, cells may migrate to the target tissue, where they ideally engraft and proliferate. The lifespan of administered cells can vary significantly depending on the cell type and the patient's immune response. For example, some immune cells may have a short half-life, while stem cells may persist longer and contribute to ongoing tissue repair.

Pregnancy

There is limited data on the safety of this drug during pregnancy. It should be used only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when administering this drug to breastfeeding mothers, as it may pass into breast milk and affect the nursing infant.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Menopausal symptoms
• Vulvar and vaginal atrophy
• Prevention of osteoporosis in postmenopausal women
• Hypoestrogenism due to hypogonadism or castration

Dosage

Children: Conjugated estrogens are not typically indicated for use in the pediatric population. Refer to specialized resources for any off-label use.

Adults: Refer to the BNF for specific dosing guidelines, as doses may vary based on the indication and patient-specific factors.

Mechanism of action

Conjugated estrogens exert their effects primarily through binding to estrogen receptors, leading to the activation of estrogen-responsive genes. This binding triggers a cascade of biological responses that promote the development and maintenance of female reproductive tissues, regulation of the menstrual cycle, and other systemic effects such as bone density maintenance and modulation of cholesterol levels.

Pharmacodynamics

The pharmacodynamics of conjugated estrogens involve their role in modulating gene expression within estrogen-responsive tissues. They help to alleviate symptoms associated with menopause, such as hot flashes and vaginal dryness, and play a critical role in bone health by inhibiting osteoclast activity, thus reducing bone resorption and helping to prevent osteoporosis.

Pharmacokinetics

Following oral administration, conjugated estrogens are absorbed through the gastrointestinal tract. They undergo first-pass metabolism in the liver, which can affect their bioavailability. The half-life of conjugated estrogens varies, but they generally have a half-life of several hours. They are metabolized primarily in the liver and excreted in urine. The pharmacokinetics can be influenced by factors such as age, liver function, and concurrent medications.

Contra-indications

• Known hypersensitivity to conjugated estrogens or any of the excipients
• Estrogen-dependent neoplasms, including breast cancer
• Undiagnosed abnormal genital bleeding
• Active or past venous thromboembolic disorders
• Severe liver dysfunction or disease
• Pregnancy

Adverse effects

• Nausea
• Headache
• Breast tenderness
• Abdominal cramps
• Bloating
• Mood changes
• Increased risk of thromboembolic events
• Hypertension
• Cholestatic jaundice
• Gallbladder disease

Interactions

• Anticoagulants may have altered effects
• Certain anticonvulsants may reduce efficacy of estrogen therapy
• Rifampicin and other enzyme inducers may decrease effectiveness
• St. John's Wort may decrease hormone levels

Precautions

• Monitor patients for signs of thromboembolic disorders
• Assess risk factors for cardiovascular disease
• Evaluate liver function before and during treatment
• Consider individual patient history of breast cancer or other estrogen-sensitive conditions

Pregnancy

Conjugated estrogens are contraindicated in pregnancy due to risk of fetal harm.

Breast-feeding

Conjugated estrogens may be excreted in breast milk; use with caution in breastfeeding women.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

• Oral tablets
• Injectable forms

Indications

• Prevention of diphtheria through vaccination
• Treatment of diphtheria infection
• Management of respiratory obstruction due to pseudomembrane

Dosage

Children: Refer to specific

Adults: Refer to specific guidelines for the treatment of diphtheria. Antitoxin and antibiotics are typically used in treatment.

Mechanism of action

The pathogenicity of Corynebacterium diphtheriae is largely due to its production of diphtheria toxin, an A-B toxin that inhibits protein synthesis in host cells. The toxin is composed of two subunits: the A subunit, which enters the cytoplasm of the cell and catalyzes the ADP-ribosylation of elongation factor 2 (EF-2), leading to cell death, and the B subunit, which binds to the cell surface receptor, facilitating the entry of the A subunit. This results in local tissue damage and systemic effects, including myocarditis and neuropathy.

Pharmacodynamics

Diphtheria toxin exerts its effects primarily through inhibiting protein synthesis, causing cell death in susceptible tissues. The resulting necrosis can lead to the characteristic pseudomembrane formation in the throat and can affect other organs, including the heart and nervous system. The immune response to the toxin and the bacteria provides some level of protection, which is the basis for vaccination strategies.

Pharmacokinetics

The pharmacokinetics of the diphtheria toxin itself are not typically described in terms of absorption, distribution, metabolism, and excretion, as it is a potent toxin rather than a conventional drug. However, the body’s immune response to the toxin is crucial for recovery. After vaccination, the body generates antibodies against the toxin, which can neutralize its effects upon exposure to the bacterium.

Pregnancy

Diphtheria vaccination is recommended during pregnancy to protect the mother and fetus. The vaccine is inactivated and poses no risk.

Breast-feeding

Diphtheria vaccination is safe during breastfeeding. Antibodies may be transferred to the infant through breast milk.

Storage

Store in a refrigerator at 2-8 degrees Celsius. Do not freeze.

Formulations

• Diphtheria toxoid vaccine

Indications

• Bacterial meningitis
• Pneumonia
• Epiglottitis
• Otitis media
• Sinusitis
• Bronchitis

Dosage

Children: Refer to specific antibiotic guidelines for pediatric dosing based on the type and severity of the infection caused by Haemophilus species.

Adults: Refer to specific antibiotic guidelines for dosing based on the type and severity of the infection caused by Haemophilus species.

Mechanism of action

H. influenzae adheres to epithelial cells via pili and other surface structures, allowing colonization of the nasopharynx. The encapsulated strains evade phagocytosis due to their polysaccharide capsule, which inhibits opsonization and complement activation. This leads to the systemic spread of the bacteria and can result in severe infections if not effectively treated.

Pharmacodynamics

H. influenzae can produce various virulence factors, including polysaccharide capsules, endotoxins, and enzymes that contribute to its pathogenicity. The bacteria can resist the effects of certain antibiotics through mechanisms such as beta-lactamase production, which hydrolyzes beta-lactam antibiotics, rendering them ineffective. The host's immune response is often inadequate to clear the infection due to the bacterium's ability to evade immune detection.

Pharmacokinetics

The pharmacokinetics of antibiotics used to treat H. influenzae infections vary based on the specific drug. Common antibiotics include ampicillin and ceftriaxone. The absorption, distribution, metabolism, and excretion depend on the antibiotic used. For example, ampicillin is well absorbed from the gastrointestinal tract, widely distributed in body tissues and fluids, and eliminated primarily via renal excretion.

Adverse effects

• Injection site reactions
• Fever
• Rash
• Irritability
• Anaphylaxis (rare)

Precautions

• Caution in patients with a history of severe allergic reactions
• Monitor for signs of anaphylaxis after administration
• Assess for underlying immunocompromised conditions

Pregnancy

Safety during pregnancy has not been established; use only if clearly needed.

Breast-feeding

Generally considered safe, but consult a healthcare provider.

Storage

Store at 2-8 degrees Celsius. Do not freeze. Protect from light.

Formulations

• Injectable suspension
• Oral tablets

Indications

• Hepatitis A
• Hepatitis B
• Influenza
• Polio
• Rabies
• Typhoid fever

Dosage

Children: Refer to specific product guidelines for paediatric dosing, as it varies by vaccine type and indication.

Adults: Refer to specific product guidelines for adult dosing, as it varies by vaccine type and indication.

Mechanism of action

Inactivated vaccines work by introducing a form of the pathogen that cannot cause disease into the body. This stimulates the immune system to produce antibodies and memory cells specific to the pathogen, allowing for a robust immune response upon future exposure. The immune system recognizes the inactivated pathogen as foreign, leading to the activation of T-cells and B-cells, which are crucial for long-term immunity.

Pharmacodynamics

The pharmacodynamics of inactivated vaccines involve the generation of an adaptive immune response. After vaccination, the body produces specific antibodies against the inactivated pathogen. The response typically includes both humoral immunity, characterized by antibody production, and cellular immunity, involving T-cell activation. The duration of immunity can vary, and booster doses may be required to maintain adequate protection.

Pharmacokinetics

Inactivated vaccines do not have a pharmacokinetic profile like traditional drugs since they do not enter systemic circulation in the same manner. Following administration, the vaccine components are taken up by antigen-presenting cells, which process and present the antigens to T-cells. The immune response is initiated locally at the site of injection and can be influenced by factors such as the route of administration and the presence of adjuvants that enhance the immune response.

Adverse effects

• Injection site reactions (pain, swelling, redness)
• Fever
• Fatigue
• Headache
• Myalgia
• Chills

Precautions

• Assess for allergies to vaccine components
• Monitor for allergic reactions post-administration
• Consider underlying health conditions that may affect immune response

Pregnancy

Inactivated vaccines are generally considered safe during pregnancy, but individual risk-benefit assessment is recommended.

Breast-feeding

Inactivated vaccines can be administered during breastfeeding without concern for adverse effects in the infant.

Storage

Store in a refrigerator at 2°C to 8°C. Do not freeze.

Formulations

• Inactivated viral vaccines
• Inactivated bacterial vaccines

Indications

• Influenza virus infection
• Prophylaxis of influenza in high-risk populations
• Treatment of suspected or confirmed influenza in children and adults

Dosage

Children: Refer to the specific antiviral medication's product information for dosing guidance.

Adults: Refer to the specific antiviral medication's product information for dosing guidance.

Mechanism of action

Antiviral medications targeting influenza, such as neuraminidase inhibitors (e.g., oseltamivir), work by inhibiting the neuraminidase enzyme on the surface of the virus. This inhibition prevents the release of new viral particles from infected cells, thus limiting the spread of the virus within the respiratory tract.

Pharmacodynamics

The pharmacodynamic effects of antiviral agents against influenza include a reduction in the severity and duration of symptoms, as well as a decrease in the viral load. Neuraminidase inhibitors are most effective when administered within 48 hours of the onset of symptoms, as they can significantly reduce the duration of illness and the risk of complications.

Pharmacokinetics

Antivirals such as oseltamivir are administered orally and are quickly absorbed from the gastrointestinal tract. The drug is converted to its active form, oseltamivir carboxylate, primarily in the liver. It has a half-life of approximately 6 to 10 hours and is predominantly eliminated via the kidneys. Patients with renal impairment may require dose adjustments to avoid toxicity.

Pregnancy

Consult healthcare provider for risks and benefits.

Breast-feeding

Consult healthcare provider for risks and benefits.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Whooping cough (pertussis)
• Prevention of pertussis in infants and young children through vaccination

Dosage

Children: Refer to the BNF for Children for specific dosing information.

Adults: Refer to the BNF for specific dosing information.

Mechanism of action

Pertussis toxin, produced by Bordetella pertussis, acts on host cells by ADP-ribosylating a G protein, which disrupts normal signal transduction pathways. This leads to increased production of cyclic AMP, inhibiting immune responses and contributing to the characteristic symptoms of the disease.

Pharmacodynamics

The clinical manifestations of pertussis are largely due to the immune response to the toxin and the bacterium itself. The disease progresses through stages: the catarrhal stage with mild symptoms, the paroxysmal stage with intense coughing fits, and the convalescent stage where symptoms gradually improve. The severity can vary, particularly in infants and young children, who are at higher risk for complications.

Pharmacokinetics

The pharmacokinetics of Bordetella pertussis are not typically described in the same manner as pharmaceutical agents. The organism does not have a traditional pharmacokinetic profile, but it primarily colonizes the ciliated epithelial cells of the upper respiratory tract. The immune clearance of the bacteria can take several weeks, depending on the host's immune response and treatment.

Adverse effects

• Cough
• Vomiting
• Fatigue
• Apnea (especially in infants)
• Weight loss
• Paroxysms of coughing
• Encephalopathy (rare)
• Pneumonia (secondary infection)

Precautions

• Use with caution in individuals with a history of seizures
• Consider potential for severe respiratory distress, especially in infants
• Monitor for complications, particularly in young children

Pregnancy

Pertussis vaccination is recommended during pregnancy to protect the newborn, especially during outbreaks.

Breast-feeding

Vaccination during breastfeeding is safe and can provide passive immunity to the infant.

Storage

Store in a cool, dry place away from direct sunlight. Follow specific storage instructions for vaccines.

Formulations

• DTaP vaccine (Diphtheria, Tetanus, and Pertussis)
• Tdap vaccine (Tetanus, Diphtheria, and Pertussis)

Indications

• Prevention of poliomyelitis infection
• Vaccination in children and high-risk populations

Dosage

Children: Refer to the BNF for Children for specific dosages and recommendations for vaccination schedules.

Adults: Refer to specific vaccination guidelines for adults, as dosages may vary based on risk factors and prior vaccination history.

Mechanism of action

Poliovirus enters the body through the oral route, replicating in the oropharynx and gastrointestinal tract before spreading to the central nervous system via the bloodstream. Once inside the CNS, the virus selectively infects motor neurons in the anterior horn of the spinal cord, leading to cell lysis and resulting in muscle weakness or paralysis. The immune response to the virus contributes to inflammation and further neuronal damage.

Pharmacodynamics

The poliovirus's pathogenicity is primarily due to its ability to evade the host's immune response and its selective neurotropism. The destruction of motor neurons leads to flaccid paralysis, with recovery possible in some cases as the motor neurons may regenerate. The severity of the disease correlates with the extent of neuronal involvement, which can vary widely among individuals.

Pharmacokinetics

Poliovirus is an RNA virus that does not undergo traditional pharmacokinetic processes as it is not treated with drugs. Instead, the prevention of polio relies on vaccination strategies. The inactivated poliovirus vaccine (IPV) and the oral poliovirus vaccine (OPV) are used to induce immunity. After administration, the vaccines promote the development of antibodies against the virus without causing disease.

Contra-indications

• Hypersensitivity to the vaccine component
• Severe immunodeficiency
• Acute febrile illness

Adverse effects

• Pain at injection site
• Fever
• Fatigue
• Headache
• Nausea
• Allergic reactions

Interactions

• Immunosuppressive therapies may reduce vaccine efficacy
• Concomitant administration with other vaccines may affect immune response

Precautions

• Use with caution in individuals with moderate to severe acute illness
• Consider history of allergic reactions
• Monitor for signs of anaphylaxis after administration

Pregnancy

Poliomyelitis vaccination is generally considered safe during pregnancy, but consult a healthcare professional.

Breast-feeding

The vaccine is considered safe for breastfeeding mothers.

Storage

Store at 2 to 8 degrees Celsius. Do not freeze. Protect from light.

Formulations

• Inactivated poliovirus vaccine (IPV)
• Oral poliovirus vaccine (OPV)

Indications

• Nutritional supplementation
• Muscle repair and growth
• Immune support
• Enzyme replacement therapy
• Hormonal regulation

Dosage

Children: Refer to specific product guidelines for dosing information, as protein requirements in children vary based on age, growth stage, and health status.

Adults: Refer to specific product guidelines for dosing information, as protein requirements can vary widely based on individual needs, activity levels, and clinical conditions.

Mechanism of action

Proteins exert their effects primarily through their structure and interactions with other molecules. They can function as enzymes, hormones, and antibodies, and their action is often mediated by binding to specific receptors or substrates, leading to a change in cellular activity or function. For example, enzymes catalyze biochemical reactions, while antibodies bind to antigens to facilitate immune responses.

Pharmacodynamics

The pharmacodynamics of proteins can vary significantly depending on the specific protein being considered. Generally, the effects of proteins are dose-dependent and influenced by their concentration, affinity for targets, and duration of action. Proteins can have a wide range of biological activities, including promoting cellular repair, regulating metabolism, and modulating immune responses.

Pharmacokinetics

The pharmacokinetics of proteins includes their absorption, distribution, metabolism, and excretion (ADME). Proteins are typically digested in the gastrointestinal tract into amino acids before being absorbed into the bloodstream. Once in circulation, proteins can be distributed throughout various tissues. They may have a variable half-life based on their structure and function, and they are primarily metabolized by the liver and excreted via the kidneys. The pharmacokinetic profile can be influenced by factors such as the route of administration and the presence of other substances.

Pregnancy

Generally considered safe, but high protein intake should be monitored to avoid potential risks.

Breast-feeding

Adequate protein intake is critical for lactating women to support milk production and quality.

Storage

Store in a cool, dry place, away from direct sunlight.

Indications

• Tetanus prophylaxis in individuals at risk
• Management of tetanus infection (including generalized tetanus and localized tetanus)
• Post-exposure prophylaxis following contaminated wounds

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations based on age and weight.

Adults: Refer to the BNF for specific dosing recommendations based on clinical presentation and vaccination history.

Mechanism of action

The tetanus toxin binds to motor neurons and prevents the release of neurotransmitters that inhibit muscle contractions, leading to sustained muscle contraction and spasms. This action disrupts normal synaptic transmission at the neuromuscular junction, causing the characteristic symptoms of tetanus.

Pharmacodynamics

Tetanus toxin is highly potent, with a lethal dose estimated to be in the range of nanograms. It acts by inhibiting glycine and gamma-aminobutyric acid (GABA) release, which are crucial for inhibitory neurotransmission, resulting in unopposed stimulation of motor neurons. This leads to the hallmark rigidity and spasms seen in tetanus.

Pharmacokinetics

The pharmacokinetics of tetanus toxin involve its absorption at the site of infection, followed by transport via retrograde axonal movement to the central nervous system, where it exerts its effects. The onset of symptoms can vary based on the distance of the wound from the central nervous system and the amount of toxin produced. The duration of action can be prolonged due to the toxin's binding to nerve endings, which can remain for weeks to months.

Adverse effects

• Muscle spasms
• Fever
• Sweating
• High blood pressure
• Rapid heart rate
• Difficulty swallowing
• Respiratory failure in severe cases

Precautions

• Ensure proper vaccination status prior to administration.
• Monitor for signs of anaphylaxis after administration.
• Use with caution in patients with cardiovascular disease.

Pregnancy

Safety in pregnancy is not well established. Consult healthcare providers for risk assessment.

Breast-feeding

Limited data available. Caution is advised.

Storage

Store vials in a refrigerator at 2-8°C. Protect from light.

Formulations

• Tetanus toxoid vaccine
• Tetanus immunoglobulin

Indications

• Tetanus prophylaxis
• Treatment of tetanus infection
• Management of tetanus symptoms

Dosage

Children: Refer to the specific guidelines for tetanus immunoglobulin and other supportive treatments as per clinical protocols.

Adults: Refer to the specific guidelines for tetanus immunoglobulin and other supportive treatments as per clinical protocols.

Mechanism of action

The tetanus toxin binds to the presynaptic membrane of motor neurons and is transported retrogradely to the spinal cord, where it interferes with neurotransmitter release, particularly inhibiting the release of glycine and gamma-aminobutyric acid (GABA), leading to unopposed motor neuron activity and resultant muscle rigidity and spasms.

Pharmacodynamics

Tetanus toxin is one of the most potent toxins known, with effects that can manifest within hours of exposure. The toxin's ability to block inhibitory neurotransmitter release results in a state of continuous muscle contraction, known as tetany. The clinical presentation of tetanus includes trismus (lockjaw), muscle rigidity, and autonomic instability, among others.

Pharmacokinetics

The pharmacokinetics of tetanus toxin are complex due to its high potency and the nature of its action. Following entry into the body, the toxin binds to nerve endings and is internalized, leading to its effects on neurotransmitter release. The half-life of the toxin is not well defined as it does not circulate freely in the bloodstream but acts locally at the neuromuscular junction. Recovery from the effects of the toxin may take weeks to months, depending on the severity of the infection and the treatment provided.

Adverse effects

• Pain at the injection site
• Fever
• Fatigue
• Headache
• Nausea

Precautions

• Ensure patient is up to date with vaccinations
• Monitor for allergic reactions post-vaccination
• Consider history of neurological disorders

Pregnancy

Tetanus vaccination is considered safe during pregnancy and is recommended to protect both the mother and the newborn.

Breast-feeding

Tetanus vaccination is safe during breastfeeding and does not affect the nursing infant.

Storage

Store in a refrigerator at 2–8 degrees Celsius. Do not freeze.

Formulations

• Tetanus toxoid vaccine

Indications

• Diphtheria prophylaxis
• Tetanus prophylaxis
• Pertussis prophylaxis (when combined with other vaccines)

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations for pediatric immunization with toxoids.

Adults: Refer to specific guidelines for each toxoid vaccine, as dosing may vary based on the type of vaccine and individual patient factors.

Mechanism of action

Toxoids work by stimulating the immune system to produce antibodies against the toxin without causing disease. When administered, the immune system recognizes the toxoid as a foreign substance and generates a specific immune response. This includes the production of immunoglobulin G (IgG) antibodies that can neutralize the active toxin if the individual is exposed to the bacteria in the future.

Pharmacodynamics

The pharmacodynamics of toxoids involve the activation of the adaptive immune response. After vaccination, dendritic cells present the antigen to T cells, which then help B cells differentiate into plasma cells that produce specific antibodies. The presence of these antibodies provides immunity against the toxin by neutralizing its effects, thereby preventing the disease associated with the original bacterial toxin.

Pharmacokinetics

Toxoids are typically administered via intramuscular or subcutaneous injection. Following administration, they are gradually taken up by antigen-presenting cells, which then process and present the toxoid to T cells. The immunogenic response can develop over several weeks. The duration of immunity can vary, necessitating booster doses to maintain adequate antibody levels over time.

Adverse effects

• Local reactions at the injection site, such as pain, swelling, or redness.
• Fever.
• Fatigue.
• Headache.
• Allergic reactions in rare cases.

Precautions

• Use with caution in individuals with a history of severe allergic reactions to a vaccine component.
• Monitor patients for allergic reactions post-vaccination.

Pregnancy

Toxoids are generally considered safe during pregnancy; however, consultation with a healthcare provider is recommended.

Breast-feeding

Toxoids are considered safe for use during breastfeeding.

Storage

Store in a refrigerator at 2-8°C. Do not freeze. Protect from light.

Formulations

• Diphtheria toxoid
• Tetanus toxoid
• Pertussis toxoid

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.

Dosage

Children: Paediatric dosing for whole products also varies and should be determined by specific products and clinical considerations; consult relevant paediatric pharmacology references for precise information.

Adults: Dosage for whole products is highly variable and should be guided by specific formulations and the clinical context; refer to the appropriate pharmacological references for guidance.

Mechanism of action

The mechanism of action for whole substances varies widely based on the specific plant or compound. Generally, phytochemicals in whole herbs may interact with various biological pathways, such as modulating the immune response, influencing neurotransmitter systems, or exhibiting antioxidant properties. For example, compounds like flavonoids and alkaloids can affect cellular signaling pathways and may impact inflammation, metabolism, or cell proliferation.

Pharmacodynamics

Pharmacodynamics of whole substances also varies greatly. The active compounds may exhibit dose-dependent effects, where low concentrations could stimulate certain biological pathways while higher concentrations may have inhibitory effects. The synergy among multiple components in whole products can enhance efficacy and reduce toxicity compared to isolated compounds, contributing to their therapeutic profiles.

Pharmacokinetics

The pharmacokinetics of whole herbal preparations depend on the specific constituents present. These factors include absorption rates, distribution throughout the body, metabolism (often involving hepatic pathways), and excretion (typically via renal pathways). The complex mixture of compounds can affect bioavailability and the overall pharmacokinetic profile, with some components exhibiting prolonged half-lives or effects due to their interaction with metabolic enzymes.

Pregnancy

The safety of this drug during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known if this drug is excreted in human milk. Caution is advised when administering to nursing mothers.

Storage

Store in a cool, dry place, away from direct light. Keep out of reach of children.